These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 14759228

  • 1. Elements of design: the knowledge on which we build.
    MacGowan AP.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
    [Abstract] [Full Text] [Related]

  • 2. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
    MacGowan AP, Noel AR, Rogers CA, Bowker KE.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML, García Y, Valero E, Amores R, Fuentes F.
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 6. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
    [Abstract] [Full Text] [Related]

  • 7. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 8. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V, Thorburn CE, Knott SJ, Woodnutt G.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [Abstract] [Full Text] [Related]

  • 9. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 10. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.
    Dagan R.
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S21-6. PubMed ID: 12839704
    [Abstract] [Full Text] [Related]

  • 11. Proof of concept: performance testing in models.
    Craig WA.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain.
    Isla A, Trocóniz IF, Canut A, Labora A, Martín-Herrero JE, Pedraz JL, Gascón AR.
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):167-73. PubMed ID: 21334779
    [Abstract] [Full Text] [Related]

  • 13. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM, Prause JL, Danziger LH, Pendland SL.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [Abstract] [Full Text] [Related]

  • 14. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R, Alou L, Giménez MJ, Sevillano D, Gómez-Lus ML, Aguilar L, Prieto J.
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [Abstract] [Full Text] [Related]

  • 15. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V, Hoover J, Singley C, Woodnutt G.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
    [Abstract] [Full Text] [Related]

  • 16. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
    Easton J, Noble S, Perry CM.
    Drugs; 2003 Mar; 63(3):311-40. PubMed ID: 12534334
    [Abstract] [Full Text] [Related]

  • 17. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2375-9. PubMed ID: 9736566
    [Abstract] [Full Text] [Related]

  • 18. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
    Jehl F, Klossek JM, Peynegre R, Serrano E, Castillo L, Bobin S, Desprez D, Renault C, Neel V, Rouffiac E, Borie C.
    Presse Med; 2002 Oct 19; 31(34):1596-603. PubMed ID: 12426976
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov 19; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug 19; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.